Show simple item record

dc.contributor.authorMartin, Daniel
dc.contributor.authorBrew-Graves, C
dc.contributor.authorMcCartan, N
dc.contributor.authorJell, G
dc.contributor.authorPotyka, I
dc.contributor.authorStevens, J
dc.contributor.authorWilliams, NR
dc.contributor.authorMcNeil, M
dc.contributor.authorO’Driscoll, BR
dc.contributor.authorMythen, M
dc.contributor.authorGrocott, MPW
dc.date.accessioned2020-07-09T13:16:28Z
dc.date.available2020-07-09T13:16:28Z
dc.date.issued2019-01-17
dc.identifier.issn2044-6055
dc.identifier.issn2044-6055
dc.identifier.otherARTN e021674
dc.identifier.urihttp://hdl.handle.net/10026.1/15933
dc.description.abstract

<jats:sec><jats:title>Introduction</jats:title><jats:p>Oxygen is the most commonly administered drug to mechanically ventilated critically ill adults, yet little is known about the optimum oxygen saturation (SpO<jats:sub>2</jats:sub>) target for these patients; the current standard of care is an SpO<jats:sub>2</jats:sub>of 96% or above. Small pilot studies have demonstrated that permissive hypoxaemia (aiming for a lower SpO<jats:sub>2</jats:sub>than normal by using a lower fractional inspired oxygen concentration (FIO<jats:sub>2</jats:sub>)) can be achieved in the critically ill and appears to be safe. This approach has not been evaluated in a National Health Service setting. It is possible that permissive hypoxaemia may be beneficial to critically ill patients thus it requires robust evaluation.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>Targeted OXygen therapY in Critical illness (TOXYC) is a feasibility randomised controlled trial (RCT) to evaluate whether recruiting patients to a study of permissive hypoxaemia is possible in the UK. It will also investigate biological mechanisms that may underlie the links between oxygenation and patient outcomes. Mechanically ventilated patients with respiratory failure will be recruited from critical care units at two sites and randomised (1:1 ratio) to an SpO<jats:sub>2</jats:sub>target of either 88%–92% or ≥96% while intubated with an endotracheal tube. Clinical teams can adjust FIO<jats:sub>2</jats:sub>and ventilator settings as they wish to achieve these targets. Clinical information will be collected before, during and after the intervention and blood samples taken to measure markers of systemic oxidative stress. The primary outcome of this study is feasibility, which will be assessed by recruitment rate, protocol adherence and withdrawal rates. Secondary outcomes will include a comparison of standard critical care outcome measures between the two intervention groups, and the measurement of biomarkers of systemic oxidative stress. The results will be used to calculate a sample size, likely number of sites and overall length of time required for a subsequent large multicentre RCT.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>This study was approved by the London - Harrow Research Ethics Committee on 2 November 2017 (REC Reference 17/LO/1334) and received HRA approval on 13 November 2017. Results from this study will be disseminated in peer-reviewed journals, at medical and scientific meetings, in the NIHR Journals Library and patient information websites.</jats:p></jats:sec><jats:sec><jats:title>Trial registration number</jats:title><jats:p><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NCT03287466" ext-link-type="clintrialgov" specific-use="clinicaltrial pre-results">NCT03287466</jats:ext-link>; Pre-results.</jats:p></jats:sec>

dc.format.extente021674-e021674
dc.format.mediumElectronic
dc.languageen
dc.language.isoen
dc.publisherBMJ
dc.subjectartificial respiration
dc.subjecthypoxia
dc.subjectoxidative stress
dc.subjectoxygen
dc.subjectrespiratory insufficiency
dc.subjectBiomarkers
dc.subjectCritical Care
dc.subjectCritical Illness
dc.subjectFeasibility Studies
dc.subjectHumans
dc.subjectHypoxia
dc.subjectMulticenter Studies as Topic
dc.subjectOxidative Stress
dc.subjectOxygen
dc.subjectOxygen Inhalation Therapy
dc.subjectRandomized Controlled Trials as Topic
dc.subjectReactive Oxygen Species
dc.subjectRespiration, Artificial
dc.subjectRespiratory Insufficiency
dc.subjectUnited Kingdom
dc.titleProtocol for a feasibility randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients
dc.typejournal-article
dc.typeClinical Trial Protocol
dc.typeJournal Article
dc.typeResearch Support, Non-U.S. Gov't
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000471116800017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue1
plymouth.volume9
plymouth.publication-statusPublished
plymouth.journalBMJ Open
dc.identifier.doi10.1136/bmjopen-2018-021674
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeEngland
dcterms.dateAccepted2018-10-29
dc.rights.embargodate2020-7-18
dc.identifier.eissn2044-6055
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1136/bmjopen-2018-021674
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2019-01-17
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV